Molecular structure of Sulfaphenazole, CAS Number: 526-08-9
Sulfaphenazole (CAS 526-08-9)
See product citations (7)
Alternate Names:
4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide
Application:
Sulfaphenazole is a specific inhibitor of CYP2C9
CAS Number:
526-08-9
Purity:
≥98%
Molecular Weight:
314.36
Molecular Formula:
C15H14N4O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Sulfaphenazole is an inhibitor of cytochrome P450 enzymes, CYP2C9 and CYP2C19. It is a competitive inhibitor of these enzymes, meaning it competes with their substrates for binding to the active site. Sulfaphenazole is a sulfonamide derivative, containing a sulfonamide functional group that is known to interact with the heme iron of the cytochrome P450 enzymes.
Sulfaphenazole (CAS 526-08-9) References
- Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. | Viswanathan, S., et al. 2003. J Am Coll Nutr. 22: 502-10. PMID: 14684755
- Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice. | Elmi, S., et al. 2008. Vascul Pharmacol. 48: 1-8. PMID: 17974492
- Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation. | Khan, M., et al. 2009. Antioxid Redox Signal. 11: 725-38. PMID: 18855521
- Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. | Giannarelli, C., et al. 2009. Circulation. 119: 1625-33. PMID: 19289643
- A sulfaphenazole-sensitive EDHF opposes platelet-endothelium interactions in vitro and in the hamster microcirculation in vivo. | Krötz, F., et al. 2010. Cardiovasc Res. 85: 542-50. PMID: 19717402
- The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. | Virdis, A., et al. 2010. J Clin Endocrinol Metab. 95: 920-7. PMID: 20022989
- Sulfaphenazole attenuates myocardial cell apoptosis accompanied with cardiac ischemia-reperfusion by suppressing the expression of BimEL and Noxa. | Ishihara, Y. and Shimamoto, N. 2012. J Pharmacol Sci. 119: 251-9. PMID: 22785021
- Effects of sulfaphenazole after collagenase-induced experimental intracerebral hemorrhage in rats. | Hama, S., et al. 2012. Biol Pharm Bull. 35: 1849-53. PMID: 23037177
- Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. | Chimalakonda, KC., et al. 2013. Drug Metab Lett. 7: 34-8. PMID: 24329780
- Resveratrol alters human endothelial cells redox state and causes mitochondrial-dependent cell death. | Posadino, AM., et al. 2015. Food Chem Toxicol. 78: 10-6. PMID: 25656643
- The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition. | Chen, H., et al. 2021. Bioorg Med Chem Lett. 40: 127924. PMID: 33705901
- Sulfaphenazole reduces thermal and pressure injury severity through rapid restoration of tissue perfusion. | Turner, CT., et al. 2022. Sci Rep. 12: 12622. PMID: 35871073
- Pharmacokinetics of sulfaphenazole in sheep. | Odegaard, SA. 1986. Acta Vet Scand. 27: 243-9. PMID: 3799400
Inhibitor of:
CYP11B1, CYP2B1, CYP2C9, and CYP3A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sulfaphenazole, 1 g | sc-215926 | 1 g | $307.00 |